SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

EXACT Sciences Corporation – ‘8-K’ for 3/18/21

On:  Thursday, 3/18/21, at 4:04pm ET   ·   For:  3/18/21   ·   Accession #:  1124140-21-38   ·   File #:  1-35092

Previous ‘8-K’:  ‘8-K’ on / for 3/3/21   ·   Next:  ‘8-K’ on 5/3/21 for 4/27/21   ·   Latest:  ‘8-K’ on / for 5/4/21

Magnifying glass tilted right emoji
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 3/18/21  EXACT Sciences Corporation        8-K:5       3/18/21   12:170K

Current Report   —   Form 8-K   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     25K 
 8: R1          Cover Page                                          HTML     46K 
10: XML         IDEA XML File -- Filing Summary                      XML     12K 
 7: XML         XBRL Instance -- exas-20210318_htm                   XML     21K 
 9: EXCEL       IDEA Workbook of Financial Reports                  XLSX      6K 
 3: EX-101.CAL  XBRL Calculations -- exas-20210318_cal               XML      7K 
 4: EX-101.DEF  XBRL Definitions -- exas-20210318_def                XML      9K 
 5: EX-101.LAB  XBRL Labels -- exas-20210318_lab                     XML     68K 
 6: EX-101.PRE  XBRL Presentations -- exas-20210318_pre              XML     33K 
 2: EX-101.SCH  XBRL Schema -- exas-20210318                         XSD     11K 
11: JSON        XBRL Instance as JSON Data -- MetaLinks               12±    17K 
12: ZIP         XBRL Zipped Folder -- 0001124140-21-000038-xbrl      Zip     12K 

‘8-K’   —   Current Report

This is an HTML Document rendered as filed.  [ Alternative Formats ]

 iX:   C:  C: 
 i 0001124140 i false00011241402021-03-182021-03-18

Washington, D.C. 20549
FORM  i 8-K
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):   i March 18, 2021
(Exact Name of Registrant as Specified in Charter)
 i Delaware  i 001-35092  i 02-0478229
(State or Other Jurisdiction
of Incorporation)
File Number)
 (I.R.S. Employer
Identification No.)
 i 5505 Endeavor Lane
 i Madison,  i WI   i 53719
(Address of Principal Executive Offices)(Zip Code)
Registrant’s telephone number, including area code:  ( i 608)  i 284-5700
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 i             Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 i            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 i             Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 i            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
 i Common Stock, $0.01 par value per share i EXAS i The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company  i 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

5.02                   Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On March 18, 2021, the Board of Directors (the “Board”) of Exact Sciences Corporation (the “Company”) appointed Paul Clancy as a Class I member of the Board. In connection with his appointment to the Board, Mr. Clancy was appointed to the Board’s Audit and Finance Committee.
Mr. Clancy, age 59, has more than 30 years of experience in financial management and strategic business planning, and served as the Executive Vice President and Chief Financial Officer of Alexion Pharmaceuticals, Inc., a biopharmaceutical company (Nasdaq: ALXN), from July 2017 to November 2019. Prior to joining Alexion, Mr. Clancy served as Executive Vice President, Finance and Chief Financial Officer of Biogen Inc., a biotechnology company (Nasdaq: BIIB), from August 2007 until June 2017. He also served as Senior Vice President of Finance of Biogen, with responsibilities for leading the treasury, tax, investor relations and business planning groups. Prior to the 2003 merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation to form Biogen, Mr. Clancy was the Vice President of Portfolio Management of Biogen. He joined Biogen in 2001 as Vice President of U.S. Marketing. Before Biogen, Mr. Clancy spent 13 years at PepsiCo Inc., a food and beverage company, serving in a variety of financial and general management positions, including Vice President and General Manager of PepsiCo’s Great West Business Unit. Mr. Clancy earned a Bachelor of Science in Finance from Babson College and an MBA from Columbia University.
Mr. Clancy will receive compensation for his service as a director in accordance with the Company’s Non-Employee Director Compensation Policy (the “Director Compensation Policy”), which was filed as Exhibit 10.25 to the Company’s Annual Report on Form 10-K filed on February 16, 2021 and which is incorporated herein by reference. Pursuant to the Director Compensation Policy, in connection with his initial appointment to the Board, Mr. Clancy received a stock award valued at $375,000.


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
By:/s/ Jeffrey T. Elliott
  Jeffrey T. Elliott
  Chief Financial Officer


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-K’ Filing    Date    Other Filings
Filed on / For Period end:3/18/21
2/16/2110-K,  4,  8-K,  SC 13G,  SC 13G/A
 List all Filings 
Filing Submission 0001124140-21-000038   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2021 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Fri., May 14, 5:31:23.1am ET